These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

659 related articles for article (PubMed ID: 23941826)

  • 1. A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro.
    Cai P; Lu P; Sharom FJ; Fang WS
    Cancer Lett; 2013 Dec; 341(2):214-23. PubMed ID: 23941826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modification of C-seco taxoids through ring tethering and substituent replacement leading to effective agents against tumor drug resistance mediated by βIII-Tubulin and P-glycoprotein (P-gp) overexpressions.
    Tang Y; Rodríguez-Salarichs J; Zhao Y; Cai P; Estévez-Gallego J; Balaguer-Pérez F; Redondo Horcajo M; Lucena-Agell D; Barasoain I; Díaz JF; Fang WS
    Eur J Med Chem; 2017 Sep; 137():488-503. PubMed ID: 28624703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lx2-32c, a novel taxane derivative, exerts anti-resistance activity by initiating intrinsic apoptosis pathway in vitro and inhibits the growth of resistant tumor in vivo.
    Zhou Q; Li Y; Jin J; Lang L; Zhu Z; Fang W; Chen X
    Biol Pharm Bull; 2012; 35(12):2170-9. PubMed ID: 23207769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-(3,4,5-trimethoxybenzoyl)-4-methyl-2-(p-tolyl) imidazol (BZML) targets tubulin and DNA to induce anticancer activity and overcome multidrug resistance in colorectal cancer cells.
    Bai Z; Liu X; Guan Q; Ding N; Wei Q; Tong B; Zhao M; Zhang W; Ma L
    Chem Biol Interact; 2020 Jan; 315():108886. PubMed ID: 31682804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
    Sampath D; Greenberger LM; Beyer C; Hari M; Liu H; Baxter M; Yang S; Rios C; Discafani C
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3459-69. PubMed ID: 16740771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Taxanes with high potency inducing tubulin assembly overcome tumoural cell resistances.
    Matesanz R; Trigili C; Rodríguez-Salarichs J; Zanardi I; Pera B; Nogales A; Fang WS; Jímenez-Barbero J; Canales A; Barasoain I; Ojima I; Díaz JF
    Bioorg Med Chem; 2014 Sep; 22(18):5078-90. PubMed ID: 25047938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
    Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
    Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
    Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel taxane, difluorovinyl-ortataxel, effectively overcomes paclitaxel-resistance in breast cancer cells.
    Rong D; Wang C; Zhang X; Wei Y; Zhang M; Liu D; Farhan H; Momen Ali SA; Liu Y; Taouil A; Guo W; Wang Y; Ojima I; Yang S; Wang H
    Cancer Lett; 2020 Oct; 491():36-49. PubMed ID: 32730778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-delivery of Se nanoparticles and pooled SiRNAs for overcoming drug resistance mediated by P-glycoprotein and class III β-tubulin in drug-resistant breast cancers.
    Zheng W; Yin T; Chen Q; Qin X; Huang X; Zhao S; Xu T; Chen L; Liu J
    Acta Biomater; 2016 Feb; 31():197-210. PubMed ID: 26612416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a lathyrane-type diterpenoid EM-E-11-4 as a novel paclitaxel resistance reversing agent with multiple mechanisms of action.
    Liu Q; Cai P; Guo S; Shi J; Sun H
    Aging (Albany NY); 2020 Feb; 12(4):3713-3729. PubMed ID: 32108588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MT-4 suppresses resistant ovarian cancer growth through targeting tubulin and HSP27.
    Pai HC; Kumar S; Shen CC; Liou JP; Pan SL; Teng CM
    PLoS One; 2015; 10(4):e0123819. PubMed ID: 25874627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe.
    Bai Z; Gao M; Zhang H; Guan Q; Xu J; Li Y; Qi H; Li Z; Zuo D; Zhang W; Wu Y
    Cancer Lett; 2017 Aug; 402():81-92. PubMed ID: 28576750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cytotoxic natural compound erianin binds to colchicine site of β-tubulin and overcomes taxane resistance.
    Yan W; Zhou Y; Yuan X; Bai P; Tang M; Chen L; Wei H; Yang J
    Bioorg Chem; 2024 Sep; 150():107569. PubMed ID: 38905886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumour activity of novel taxanes that act at the same time as cytotoxic agents and P-glycoprotein inhibitors.
    Ferlini C; Distefano M; Pignatelli F; Lin S; Riva A; Bombardelli E; Mancuso S; Ojima I; Scambia G
    Br J Cancer; 2000 Dec; 83(12):1762-8. PubMed ID: 11104578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel taxane derivatives from Taxus wallichiana with high anticancer potency on tumor cells.
    Wang Y; Wang J; Wang H; Ye W
    Chem Biol Drug Des; 2016 Oct; 88(4):556-61. PubMed ID: 27153813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
    Wong VK; Chiu P; Chung SS; Chow LM; Zhao YZ; Yang BB; Ko BC
    Clin Cancer Res; 2005 Aug; 11(16):6002-11. PubMed ID: 16115945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
    Park SJ; Wu CH; Choi MR; Najafi F; Emami A; Safa AR
    Biochem Pharmacol; 2006 Jul; 72(3):293-307. PubMed ID: 16753135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells.
    Podolski-Renić A; Banković J; Dinić J; Ríos-Luci C; Fernandes MX; Ortega N; Kovačević-Grujičić N; Martín VS; Padrón JM; Pešić M
    Eur J Pharm Sci; 2017 Jul; 105():159-168. PubMed ID: 28502672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chamaecypanone C, a novel skeleton microtubule inhibitor, with anticancer activity by trigger caspase 8-Fas/FasL dependent apoptotic pathway in human cancer cells.
    Hsieh CC; Kuo YH; Kuo CC; Chen LT; Cheung CH; Chao TY; Lin CH; Pan WY; Chang CY; Chien SC; Chen TW; Lung CC; Chang JY
    Biochem Pharmacol; 2010 May; 79(9):1261-71. PubMed ID: 20034474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.